share_log

Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting

Benzinga ·  Apr 8 07:05

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company's unique target selection strategy and strong preclinical to clinical translation observed across the Company's first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment